Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW to Issue Notification to Ensure Restricted Use of Repatha
The Ministry of Health, Labor and Welfare (MHLW) will issue a notification on April 20 upon the reimbursement listing of the hypercholesterolemia treatment Repatha (evolocumab), calling on clinicians to thoroughly follow the restrictions attached to its indication. Repatha was approved…
To read the full story
Related Article
- Japan’s 1st PCSK9 Inhibitor Hits Market; MHLW Issues Notification to Prevent Hasty Use
April 21, 2016
- Indication-Based Front-Loaded Re-Pricing, Coverage Limits Emerge for Pricey Meds: Chuikyo
April 14, 2016
- Chuikyo to Make Go or No-Go Decision on Drug Price Survey by Mid-2016
April 14, 2016
- Chuikyo OKs Repatha for NHI Price Listing on April 20, Peak Sales Projected at 49 Billion Yen
April 13, 2016
REGULATORY
- Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
- US Opens Probe into German Drug Pricing Policies; Could Japan Be Next?
June 24, 2026
- Japan Awards Sakigake Tag to AbbVie’s Bispecific Etentamig
June 24, 2026
- Japan Grants Orphan Status to Vanda, Quoin Drugs, and Lots More
June 24, 2026
- Carvykti Earlier Use Up for Japan Panel Review on June 29
June 23, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…